Eric J. Ende

Since 2009, Dr. Ende has served as President of Ende BioMedical Consulting Group. Ende BioMed is focused on helping life sciences companies raise capital, identify licensing partners and acquirers, and optimizing corporate structure. In addition, it analyzes both private and public investment opportunities for clients within the life sciences industry. Ende also helps activist investors gain seats on Company Boards.

Dr. Ende was a Director on Genzyme’s Board from 2010 – 2011 until it was acquired by Sanofi-Aventis for $21 B in 2011. During his tenure on Genzyme’s Board, he was a member of the Audit and Risk Management Committees. Ende is currently on the Board of Directors of Matinas BioPharma, where he is the Chairman of the Compensation Committee and is serving on the Audit as well as the Nomination & Governance committees. Ende is also on the Board of Directors of Avadel plc, where he is the Chairman of the Nomination & Corporate Governance Committee and is serving on the Audit & Compensation Committees. Ende was also voted to the Board of Progenics Pharmaceuticals, serving as Chair of the Compensation Committee as well as serving on the Audit and Science Committees. Ende is also on the Technology Transfer Committee of Mount Sinai Innovation Partners. He also served as the Chairman of the Unsecured Creditor’s Committee overseeing the Egenix Bankruptcy and on the subsequent Liquidating Trust Committee.

From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 – 2002, Ende was the senior biotechnology analyst at Banc of America Securities. And, from 1997 – 2000, he was a biotechnology analyst at Lehman Brothers. During Dr. Ende’s career as a biotechnology analyst, he was named to Institutional Investor’s All-America Equity Research Team six times as well as to The Greenwich Survey list of top analysts. He was also named Top Stock Picker by The Street.com and Best Earnings Estimator by Forbes.com.

Dr. Ende received an MBA in Finance & Accounting from NYU – Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990.